IOncology

Monoclonal antibody-based targeted therapy has significantly improved treatment options for cancer patients. In recent years, advancements in protein engineering have led to the development of bispecific antibodies (BsAbs), marking a paradigm shift in antibody construction usage. BsAbs, recognized for their higher therapeutic response, resistance barrier, and fewer adverse reactions, have caught significant attention in the academic world. The next wave of "bispecific or multispecific antibodies" is also on the horizon. At the 50th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting, Professor Maria Gomes Da Silva from the Portuguese Oncology Institute delivered an insightful report on the latest advances in BsAb treatments for lymphoma. "Oncology Frontier - Hematology Frontier" invited Professor Da Silva to share the latest developments and challenges in this field with our readers.

Acute Lymphoblastic Leukemia (ALL) is a malignant neoplastic disease that originates from B-cell or T-cell lymphocytes and proliferates abnormally in the bone marrow. In recent years, immunotherapy has made significant strides in the field of ALL, including breakthroughs in treatments such as Chimeric Antigen Receptor T-cell (CAR-T) therapy, bispecific antibodies, and antibody-drug conjugates (ADC). The 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting took place in Glasgow, UK, from April 14 to 17, 2024. At the conference, Professor Peter Bader from the Department of Stem Cell Transplantation, Immunology, and Intensive Care Medicine at the University Hospital Frankfurt, Germany, delivered a special report on the current application of CAR-T therapy in ALL patients. Hematology Frontier invited Professor Bader to share the latest progress and challenges in CAR-T therapy in the field of ALL with a wide audience.

Lymphoma has become the most prevalent malignant hematological tumor in China. Enhancing the standardized diagnosis and treatment of lymphoma is crucial for improving cure rates. The "Chinese Society of Clinical Oncology (CSCO) Lymphoma Treatment Guidelines" are updated annually and play a significant role in promoting standardized care for lymphoma. At the recent 2024 CSCO Guidelines Conference, the 2024 edition of the CSCO Lymphoma Treatment Guidelines was released as scheduled. To better understand the key updates in the 2024 edition, "Oncology Frontier - Hematology Frontier" invited Professor Jun Ma, Director of the Harbin Institute of Hematology Oncology, to discuss the current status of lymphoma diagnosis and treatment in China, and to share the significance and highlights of the new guidelines.

With the development of targeted therapy and immunotherapy, the treatment options for malignant hematologic diseases continue to expand. The "Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Malignant Hematologic Diseases (2024)" has once again been updated. "Oncology Watch" specially interviewed one of the guideline's authors, Professor Tiejun Gong from the Harbin Institute of Hematology and Oncology, to provide in-depth explanations on the highlights of the guideline updates, their impact on clinical practice, and the implementation of the guidelines.